Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio

Table 1

Main characteristics of the studies included in this meta-analysis.

Author, year	Location	Tumor type	Tumor stage	Tx option	Parameter	Criteria	Criterion subgroup	Number of patients
								Total	High	Low
Alagappan et al., 2016 [24]	USA	PDAC	ND	Mixed	NLR	5	High	208	ND	ND
					PLR	200	High	208	ND	ND
An et al., 2010 [36]	China	PC	III-IV	CTx	NLR	5	High	95	ND	ND
Asaoka et al., 2016 [21]	Japan	PC	I-III	Mixed	NLR	2.7	Low	46	20	26
Asari et al., 2016 [22]	Japan	PDAC	I-IV	Mixed	NLR	3	Low	184	62	122
Ben et al., 2015 [28]	China	PDAC	I-III	Surgery	NLR	2	Low	381	267	114
Chawla et al., 2017 [37]	USA	PDAC	I-IV	Mixed	NLR	3.3	Low	217	107	110
					PLR	175	High	217	107	110
Chen et al., 2017 [10]	China	PDAC	III-IV	CTx	NLR	2.78	Low	132	78	54
Cheng et al., 2016 [25]	China	PC	I-II	Mixed	NLR	2	Low	195	128	67
Inoue et al., 2015 [30]	Japan	PDAC	I-IV	Mixed	NLR	2	Low	440	300	140
					PLR	150	Low	440	201	239
Kishi et al., 2015 [27]	Japan	PC	III/IV	CTx/RTx	NLR	5	High	65	7	58
					PLR	150	Low	65	30	35
Kou et al., 2016 [23]	Japan	PC	III-IV	CTx	NLR	5	High	306	49	257
					PLR	150	Low	306	180	126
Lee et al., 2016 [19]	Korea	PDAC	III-IV	CTx	NLR	5	High	82	20	62
					PLR	150	Low	82	36	46
Liu et al., 2017 [14]	China	PDAC	I-IV	Mixed	NLR	4.5	High	386	63	323
Luo et al., 2015 [29]	China	PDAC	III-IV	CTx	NLR	3.1	Low	403	194	209
Martin et al., 2014 [31]	Australia	PC	III-IV	CTx/RTx	NLR	5	High	124	60	64
					PLR	200	Low	124	75	49
Mitsunaga et al., 2016 [41]	Japan	PC	III-IV	CTx	NLR	5	High	195	ND	ND
Montes et al., 2017 [11]	Spain	PC	III-IV	CTx	NLR	2.455	Low	39	ND	ND
Piciucchi et al., 2017 [12]	Italy	PDAC	ND	Mixed	NLR	5	High	206	60	144
Shirai et al., 2015 [15]	Japan	PDAC	ND	ND	NLR	5	High	131	15	116
					PLR	150	Low	131	73	58
Sierzega et al., 2017 [13]	Poland	PDAC	I-III	Mixed	NLR	5	High	442	119	323
Sugiura et al., 2013 [34]	Japan	PDAC	III-IV	Mixed	NLR	4	Low	83	36	47
Sugiura et al., 2017 [9]	Japan	PDAC	III-IV	CTx	NLR	4	Low	129	62	67
Szkandera et al., 2014 [33]	Austria	PDAC	I-IV	Mixed	NLR	3.25	Low	474	247	227
Tao et al., 2016 [16]	China	PDAC	I-IV	Mixed	NLR	2.5	Low	154	84	70
					PLR	150	Low	154	81	73
Takakura et al., 2016 [26]	Japan	PC	I-III	Mixed	NLR	4.3	High	28	ND	ND
Teo et al., 2013 [40]	Ireland	PDAC	III-IV	CTx	NLR	3	Low	85	58	27
Tsujita et al., 2017 [8]	Japan	PC	II-IV	Mixed	NLR	3	Low	86	ND	ND
Vivaldi et al., 2016 [18]	Italy	PC	III-IV	CTx	NLR	4	Low	119	21	98
Wang et al., 2012 [35]	China	PDAC	I-IV	Mixed	NLR	5	High	177	32	145
Wu et al., 2016 [17]	China	PDAC	III-IV	Mixed	NLR	5	High	233	57	176
Xu et al., 2017 [38]	China	PDAC	I-IV	Mixed	NLR	3.8	Low	265	71	194
					PLR	182.1	High	265	87	178
Xue et al., 2014 [32]	Japan	PDAC	III-IV	CTx	NLR	5	High	252	40	212
					PLR	150	Low	252	148	104
Yamada et al., 2016 [20]	Japan	PC	I-IV	Mixed	NLR	3	Low	379	130	249
					PLR	150	Low	379	192	187
Yu et al., 2017 [39]	China
Training set		PC	III-IV	CTx	NLR	3.42	Low	139	93	46
Validation set		PC	III-IV	CTx	NLR	3.42	Low	225	131	94

Tx: Treatment; PDAC: pancreatic ductal adenocarcinoma; PC: pancreatic cancer; CTx: chemotherapy; RTx: radiation therapy; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; ND: no description. “Mixed” treatment indicates surgery plus chemotherapy/radiotherapy.